New Trends in the Treatment of Advanced Neurological Disease Condition — Guillain-Barré Syndrome

  • C. Guérin
Conference paper


The Guillain-Barré syndrome (GB S ), an acute polyradiculopathy with “albuminocytologic dissociation” in cerebrospinal fluid, is one of the best delineated entity among the inflammatory processes affecting the peripheral nervous system. Its pathological hallmark is a segmental demyelination of the peripheral nerve associated with interstitial and perivenous inflammatory foci. It is currently the most common cause of acute paralysis in western countries with a 1–2/100,000 prevalence rate.


Plasma Exchange Experimental Autoimmune Neuritis Segmental Demyelination French Trial Acute Paralysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Asbury AK (1978) Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 3:565–566CrossRefGoogle Scholar
  2. 2.
    Zifko U, Chen R, Remtulla H et al (1996) Respiratory electrophysiological studies in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 60:191–194PubMedCrossRefGoogle Scholar
  3. 3.
    Visser LH, Van der Meche FG, Van Doom PA et al (1995) Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 118:841–847Google Scholar
  4. 4.
    Triggs WJ, Cros D, Gominak SC et al (1992) Motor nerve inexcitability in Guillain-Barré syndrome. Brain 115:1291–1302PubMedCrossRefGoogle Scholar
  5. 5.
    Rees JH, Soudain SE, Gregson NA et al (1995) Campylobacter jejuni infection and GuillainBarré syndrome. N Eng J Med 333:1374–1379CrossRefGoogle Scholar
  6. 6.
    Hartung HP, Pollard JD, Harvey GK et al (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome — Part I. Muscle Nerve 18:137–153PubMedCrossRefGoogle Scholar
  7. 7.
    Ng KK, Howard RS, Fish DR et al (1995) Management and outcome of severe Guillain-Barré syndrome. QJM 88:243–250PubMedGoogle Scholar
  8. 8.
    Greenwood RJ, Hughes RAC, Bowden AN et al (1984) Controlled trial of plasma exchange in acute inflammatory polyradiculopathy. Lancet 1:877–879PubMedCrossRefGoogle Scholar
  9. 9.
    Osterman PO, Lundemo G, Pirskanen R et al (1984) Beneficial effects of plasma exchange in acute inflammatory polyradiculoneuropathy. Lancet 2:1296–1299PubMedCrossRefGoogle Scholar
  10. 10.
    Färkkilä M, Kinnunen E, Haapanen E et al (1987) Guillain-Barré syndrome: quantitative measurement of plasma exchange therapy. Neurology 37:837–840PubMedCrossRefGoogle Scholar
  11. 11.
    The Guillain-Barré syndrome study group (1985) Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35:1096–1104CrossRefGoogle Scholar
  12. 12.
    French cooperative group on plasma exchange in Guillain-Barré syndrome (1987) Effiiciency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 22: 753–761CrossRefGoogle Scholar
  13. 13.
    Hughes RAC, Newsom-Davis JM, Perkin GD et al (1978) Controlled trial of prednisolone in acute polyneuropathy. Lancet 2:750–753PubMedCrossRefGoogle Scholar
  14. 14.
    Guillain-Barré syndrome steroid trial group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 341:586–590Google Scholar
  15. 15.
    Van der Meché FGA, Schmitz PIM, and the Dutch Guillain-Barré study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in GuillainBarré syndrome. N Engl J Med 326:1123–1129PubMedCrossRefGoogle Scholar
  16. 16.
    Bril V, Ilse WK, Pearce R et al (1996) Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 46:100–103PubMedCrossRefGoogle Scholar
  17. 17.
    Rees J (1995) Guillain-Barré syndrome. Clinical manifestations and directions for treatment. Drugs 49:912–920PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • C. Guérin

There are no affiliations available

Personalised recommendations